财务数据和关键指标变化 - 收入为28.8百万美元,同比略有下降,主要是由于停产产品的影响,但新产品的推出正在弥补这一下降 [3] - 毛利率为58%,较上年同期有所提升,主要是由于财务流程的优化 [5] - 调整后的营业利润为3.6百万美元,占收入的12.4%,同比提升2个百分点 [3] - 调整后的EBITDA为3.9百万美元,占收入的13.6%,同比提升2个百分点 [3] - 每股调整后收益为0.04美元,较上年同期的0.05美元有所下降 [3] - 经营活动产生的现金流为3.6百万美元,较上年同期的-0.2百万美元有大幅改善 [5] 各条业务线数据和关键指标变化 - 细胞和分子技术产品收入下降12%,调整后下降3.6%,主要是由于停产产品的影响 [4] - 临床前产品收入增长10%,调整后增长11.5%,主要得益于亚太和欧洲地区的强劲增长 [4] 各个市场数据和关键指标变化 - 亚太地区收入增长强劲 - 欧洲地区收入保持稳定,整体产品线表现良好 - 美国市场收入有所下滑,主要是由于吸入和呼吸产品销售放缓 [4] 公司战略和发展方向及行业竞争 - 公司持续推出新产品,如新型MEA平台,以支持细胞水平测试在学术研究和工业应用的发展 [5] - 公司正在努力将现有的研究级产品适配到更大规模的工业应用,如CRO和制药公司 [10] - 公司看好利用细胞和器官模型取代动物实验的发展趋势,并推出相关产品以满足这一需求 [11][12] - 公司正在评估并寻求合适的并购或授权机会,以进一步完善产品组合,拓展新的增长领域 [13] 管理层对经营环境和未来前景的评论 - 管理层对2023年的指引保持乐观,预计全年收入在116-120百万美元,毛利率约60%,调整后EBITDA利润率15-17% [6] - 管理层表示,尽管可能面临一些行业和宏观经济的潜在挑战,但公司目前的状况比去年强得多,有信心继续取得进步 [6] 其他重要信息 - 公司正在优化全球库存成本核算流程,这对本季度毛利率产生了一定影响 [5] - 公司正在进行一些财务系统整合和新产品相关的资本支出 [5] - 公司已连续4个季度实现经营现金流正值,并持续大幅偿还债务,预计到2023年底净负债率将降至约2倍 [5] 问答环节重要的提问和回答 问题1 **Paul Knight 提问** 询问停产产品的影响是否按计划进行 [8] **James Green 回答** 停产产品的影响在公司预期范围内,约占4个百分点的收入下降,这一转型正在按计划进行 [8][9] 问题2 **Paul Knight 提问** 询问新产品MEA技术在不同治疗领域的适用性 [11] **James Green 回答** MEA技术可用于小分子、大分子以及细胞和基因疗法的早期毒理和安全性评估,特别适用于心脏和神经系统相关的测试 [11][12] 问题3 **Bruce Jackson 提问** 询问停产产品对各业务线的影响程度 [17] **James Green 回答** 停产产品的影响主要集中在细胞和分子技术业务线,占该业务线收入的95%以上 [17]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2023 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number 001-33957 HARVARD BIOSCIENCE, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 04-3306140 (State or other jurisdiction of Incorp ...

Harvard Bioscience, Inc. (NASDAQ:HBIO) Q1 2023 Earnings Conference Call April 25, 2023 9:00 AM ET Company Participants Dave Sirois - Director, Corporate Accounting & SEC Reporting James Green - Chairman of the Board, President & Chief Executive Officer Jennifer Cote - Interim Chief Financial Officer Conference Call Participants Bruce Jackson - Benchmark Company Paul Knight - KeyBanc Operator Good day, and thank you for standing by. Welcome to Harvard Bioscience First Quarter 2023 Earnings Conference Call. [ ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________ FORM 10-K ☒ Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2022 or ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-33957 ___________________________ HARVARD BIOSCIENCE, INC. (Exact Name of Registrant as Specified in Its Charter) De ...

Harvard Bioscience, Inc. (NASDAQ:HBIO) Q4 2022 Earnings Call Transcript March 9, 2023 8:00 AM ET Company Participants Dave Sirois - Director, Corporate Accounting & SEC Reporting Jim Green - Chairman of the Board, President & Chief Executive Officer Jennifer Cote - Interim Chief Financial Officer Conference Call Participants Bruce Jackson - Benchmark Company Harrison Schrage - KeyBanc Operator Good day, and thank you for standing by. Welcome to the Harvard Bioscience Fourth Quarter 2022 Earnings Conference ...

Enabling discovery, safety and production of tomorrow's therapeutics NASDAQ: HBIO Q4'22 Earnings Presentation Jim Green, Chairman, President & CEO Jennifer Cote, Interim CFO March 9, 2023 Forward-Looking Statements and Non-GAAP Financial Information Forward-Looking Statements Information in this presentation or in oral statements of the management of the Company may include forward-looking statements within the meaning of the federal securities laws, including the Private Securities Litigation Reform Act of ...

HBIO Overview to Investors NASDAQ: HBIO Q3'22 Earnings Presentation Jim Green, Chairman, President & CEO Mike Rossi, CFO November 8, 2022 HB Forward-Looking Statements and Non-GAAP Financial Information Forward-Looking Statements Information in this presentation or in oral statements of the management of the Company may include forward-looking statements within the meaning of the federal securities laws, including the Private Securities Litigation Reform Act of 1995. You can identify these statements by our ...

Harvard Bioscience, Inc. (NASDAQ:HBIO) Q3 2022 Earnings Conference Call November 8, 2022 4:30 PM ET Company Participants David Sirois - Director, Corporate Accounting & SEC Reporting James Green - President, CEO & Chairman Michael Rossi - CFO Conference Call Participants Paul Knight - KeyBanc Capital Markets Bruce Jackson - The Benchmark Company Operator Good day, and thank you for standing by. Welcome to the Harvard Bioscience Third Quarter 2022 Earnings Call. [Operator Instructions]. Please be advised tha ...

Harvard Bioscience, Inc. (NASDAQ:HBIO) Q2 2022 Earnings Conference Call August 4, 2022 8:00 AM ET Company Participants David Sirois - Director of Corporate Accounting & SEC Reporting Jim Green - President & Chief Executive Officer Mike Rossi - Chief Financial Officer Conference Call Participants Bruce Jackson - The Benchmark Company Paul Knight - KeyBanc Capital Markets Operator Good day, and thank you for standing by. Welcome to the Q2 2022 Harvard Bioscience, Inc. Earnings Conference Call. [Operator Instr ...

NASDAQ: HBIO Q2'22 Earnings Presentation Jim Green, Chairman, President & CEO Mike Rossi, CFO August 4, 2022 Forward-Looking Statements and Non-GAAP Financial Information Forward-Looking Statements Information in this presentation or in oral statements of the management of the Company may include forward-looking statements within the meaning of the federal securities laws, including the Private Securities Litigation Reform Act of 1995. You can identify these statements by our use of such words as "will," "g ...